About — Operon Research

Competitive Intelligence, built around the data that actually moves this industry.

Operon Research is an independent publisher covering Life Science Tools, Diagnostics, and the broader life sciences value chain. We exist to give institutional decision-makers a clearer read on the industry — informed by proprietary trackers, written by people who've spent careers in the sector, and unconstrained by the conflicts that shape sell-side coverage.

Jack Meehan, CFA

Jack is co-founder of Operon Research and leads coverage of Life Science Tools, Diagnostics, the Labs, and CROs. He has spent over fifteen years analyzing this industry on the sell-side — most recently as Partner and Senior Analyst at Nephron Research, and previously at Barclays — with a track record of non-consensus calls and institutional-grade modeling.

Operon was founded to bring that work directly to institutional readers — free of the conflicts and constraints of traditional sell-side research, and focused on what drives industry growth and competitive share shift. Jack's approach is grounded in data sourced from public filings, proprietary datasets, and alternative data sources, integrated to generate differentiated insights on market trends and competitive dynamics. This data-driven methodology has delivered value to clients over the past decade across critical inflection points: COVID-related demand surges, bioprocessing industry stocking and de-stocking cycles, competitive shifts in next-generation sequencing, and the emergence of new markets such as precision oncology testing.

Jack graduated from Lehigh University with a B.S. in Integrated Business and Engineering, where he was inducted into Phi Beta Kappa and currently serves as President of his class. He holds the Chartered Financial Analyst (CFA) designation and is based in New Jersey.

Co-Founder & Senior Architect

Kofi White

Kofi is co-founder of Operon Research and leads platform architecture and data engineering. He brings sixteen years of experience designing and delivering complex IT solutions across highly regulated industries — with a consistent focus on high-volume data movement, scalable compute infrastructure, and mission-critical system integration.

Kofi began his career at Freddie Mac as a DevOps engineer, where he streamlined and automated the delivery of large-scale data movement systems. He spent the following decade at Deloitte Consulting, serving the firm's Government & Public Services practice as a technical lead — building custom data collection agents, delivering complex integration platforms (MuleSoft, Oracle Service Bus), and architecting high-volume data processing portals (Salesforce) for clients including the Department of Treasury, Department of State, and the FDA. Most recently, Kofi has been supporting customers in the U.S. Aerospace and Defense industrial base, helping customers implement Kubernetes-based solutions enabling capabilities ranging from air-gapped LLMs to hypervisor modernization.

At Operon, Kofi is modernizing the way financial research is conducted, prepared, and delivered — building the technical infrastructure that powers Operon's proprietary data trackers, modeling platform, and subscriber experience. He holds a B.S. in Computer Science and Business from Lehigh University and is based in the Washington, D.C. area.

Jesse Coulter

Jesse is an Associate on Operon's Life Science Tools and Diagnostics team. He holds a B.S. in Mechanical Engineering and a B.S. in Integrated Business and Engineering with a concentration in Finance from Lehigh University — a dual-degree program focused on the intersection of technical and financial analysis.

Before joining Operon, Jesse worked at Nephron Research on the Life Science Tools & Diagnostics team, where he contributed to research content development and performed in-depth industry analyses across the sector. He also supported the firm's managed care practice, broadening his perspective across the healthcare landscape. Earlier in his career, Jesse gained experience in healthcare consulting, corporate finance, and project management. He is originally from Allentown, Pennsylvania.

Compliance Risk Concepts

Compliance Risk Concepts (CRC) serves as the compliance arm of Operon Research, supporting all compliance requirements for the firm. CRC brings senior-level compliance expertise rooted in practical front-office capital markets experience. CRC's methodology focuses on assessing inherent and residual business risks, then developing scalable compliance plans that leverage technology to manage regulatory demands efficiently. compliance-risk.com

Data first. Then the analysis.

Operon's research is built on a stack of proprietary trackers and datasets that we maintain continuously and refresh against every relevant data release. Each report and model is grounded in this data layer before any narrative is written.

The data layer.

Operon tracks NIH funding flows and outlays via Reporter, clinical trials activity, life sciences hiring through job postings data, web traffic patterns for the companies we cover, and other public and licensed data sources. Each tracker is designed to read against a specific question: where the dollars are flowing, where research activity is accelerating, where companies are investing in capacity, and how end-market demand is shifting in real time.

The analytical layer.

Operon's research applies decades of combined experience covering the sector to translate the data into industry read-throughs: company earnings previews and reviews, benchmarking analyses across the value chain, thematic deep dives, and our weekly Signal report.

The output.

Subscribers receive published research on a regular cadence, supported by financial models that are updated as new data lands. Operon does not issue ratings or price targets. Our focus is on what drives industry growth and competitive share shift.

Research without the conflicts.

Traditional sell-side research operates inside institutions that are also banking, trading, and lending counterparties to the companies being covered. Those conflicts shape what gets published, when, and how directly. They are managed — not eliminated.

Operon was built outside that structure. We are an independent financial publisher. We do not bank, trade, or hold positions in the companies we cover, and we do not issue investment ratings or price targets.

What that means in practice: our incentives line up with the quality of our analysis and the durability of our subscriber relationships, not with banking mandates or trading flows. Subscribers get a clearer, more direct read on the industry — written for them, not around them.